James Beebe, MD
Family Medicine · Millsboro, DENPI 1881691442
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 204 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 20.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,551 and has fallen 91.1% since, to $138 in 2025.
Across 204 payments — averaging $15.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$643
- AstraZeneca$457
- Novo Nordisk$325
- Pfizer$238
- AbbVie$238
- GSK$226
- plus $1K from 19 others
What the payments were for
- Food & beverage$3,124100%
- Education$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 33 | $643 |
| AstraZeneca | 30 | $457 |
| Novo Nordisk | 25 | $325 |
| Pfizer | 19 | $238 |
| AbbVie(2 entities) | 13 | $238 |
| GSK | 13 | $226 |
| Lilly USA, LLC | 14 | $180 |
| Boehringer Ingelheim | 9 | $135 |
| Johnson & Johnson | 10 | $126 |
| Astellas Pharma US Inc | 5 | $79 |
| Novartis | 4 | $62 |
| Kowa Pharmaceuticals America, Inc. | 3 | $57 |
| Shire North American Group Inc | 3 | $46 |
| Merck | 3 | $42 |
| Exact Sciences | 2 | $42 |
| Sumitomo Pharma America, Inc. | 2 | $38 |
| Teva Pharmaceuticals USA, Inc. | 3 | $38 |
| Amarin Pharma, Inc. | 2 | $33 |
| Daiichi Sankyo Inc. | 2 | $24 |
| Esperion Therapeutics, Inc. | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $22 |
| Dynavax Technologies Corporation | 1 | $17 |
| Livanova USA, Inc. | 1 | $16 |
| Genentech USA, Inc. | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prolia$114
How this compares
$3,135 in reported general payments places this provider in the 80th percentile of 352 family medicine providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 157 | $210,408 |
| OzempicSemaglutide | 111 | $162,469 |
| JardianceEmpagliflozin | 116 | $161,837 |
| EliquisApixaban | 86 | $115,424 |
| XareltoRivaroxaban | 22 | $34,721 |
| TrulicityDulaglutide | 11 | $28,531 |
| MyrbetriqMirabegron | 36 | $27,245 |
| Repatha SureclickEvolocumab | 25 | $24,280 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 16 | $19,145 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $18,731 |
| Breo ElliptaFluticasone/Vilanterol | 22 | $15,491 |
| VascepaIcosapent Ethyl | 12 | $11,637 |
| Atorvastatin Calcium | 631 | $11,065 |
| InvokanaCanagliflozin | 13 | $10,864 |
| Ezetimibe | 124 | $6,544 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $457 | $210,408157 claims |
| Novo NordiskOzempic | $325 | $162,469111 claims |
| Boehringer IngelheimJardiance | $135 | $161,837116 claims |
| PfizerEliquis | $238 | $115,42486 claims |
| GSKAnoro Ellipta, Trelegy Ellipta, Breo Ellipta | $226 | $53,36749 claims |
| Johnson & JohnsonXarelto, Invokana | $126 | $45,58535 claims |
| Lilly USA, LLCTrulicity | $180 | $28,53111 claims |
| Astellas Pharma US IncMyrbetriq | $79 | $27,24536 claims |
| AbbVieSynthroid | $238 | $3,33741 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 352 family medicine providers in Delaware.
Other family medicine in Millsboro
- Danielle GiddinsMillsboro$5K
- Hilary HaackMillsboro$5K
- Carolyn OconorMillsboro$3K
- Gregory PapaNew Castle$67K
- Sarah MullinsWilmington$36K
- Ashley PanichelliWilmington$27K
- Michelle PapaNewark$23K
- Maryann ConnorWilmington$21K
- Jill MackeyWilmington$20K
- Wayne TuckerBear$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.